Ann Marie Navar, MD, PhD

Associate Professor of Medicine
Affiliate Faculty Member, Duke-Margolis Center for Health Policy
Member in the Duke Clinical Research Institute
Campus mail 2400 Pratt St., Box 3850, Durham, NC 27705
Phone (919) 684-8111
In Their Words

Education and Training

  • Cardiovascular Disease Fellowship, Duke University School of Medicine, 2013 - 2016
  • Internal Medicine and Pediatrics Residency, Duke University School of Medicine, 2009 - 2013
  • Ph.D., Johns Hopkins University, 2009
  • M.D., Duke University School of Medicine, 2009
  • M.H.S., Johns Hopkins University, 2005

Publications

Mosca, Lori, Ann Marie Navar, and Nanette Kass Wenger. “Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.” J Womens Health (Larchmt), April 13, 2020. https://doi.org/10.1089/jwh.2019.8189.

PMID
32297837
Full Text

Shah, Nishant P., Neha J. Pajidipati, Robert W. McGarrah, Ann Marie Navar, Sreekanth Vemulapalli, Michael A. Blazing, Svati H. Shah, Adrian F. Hernandez, and Manesh R. Patel. “Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.” Am J Cardiol, April 7, 2020. https://doi.org/10.1016/j.amjcard.2020.03.043.

PMID
32336532
Full Text

Zeitouni, Michel, Stephanie N. Giamberardino, Robert McGarrah, Neha Pagidipati, Geoffrey S. Ginsburg, Udo Hoffmann, Ann Marie Navar, Pamela Douglas, and Svati Shah. “A NOVEL INFLAMMATORY MARKER OF GLYCOSYLATED PROTEINS IS ASSOCIATED WITH CAD AND INCIDENT EVENTS AND DEMONSTRATES AGE EFFECTS IN THE PROMISE TRIAL.” In Journal of the American College of Cardiology, 75:263–263. ELSEVIER SCIENCE INC, 2020.

Scholars@Duke

Zeitouni, Michel, Michael G. Nanna, Jie-Lena Sun, Karen Chiswell, Eric D. Peterson, and Ann Marie Navar. “EVALUATING THE 2018 AHA/ACC LIPID GUIDELINE PERFORMANCE TO IDENTIFY PATIENTS AT HIGH RISK FOR PREMATURE CARDIOVASCULAR DISEASE.” In Journal of the American College of Cardiology, 75:1981–1981. ELSEVIER SCIENCE INC, 2020.

Scholars@Duke

Derington, Catherine G., Jordan King, Robert S. Rosenson, Bharat Poudel, Keri Monda, Ann Navar, Katherine Mues, et al. “PCSK9 INHIBITOR INITIATION AMONG VETERANS ACCORDING TO THE 2018 AHA/ACC BLOOD CHOLESTEROL GUIDELINES.” In Journal of the American College of Cardiology, 75:233–233. ELSEVIER SCIENCE INC, 2020.

Scholars@Duke

Nanna, Michael G., Ann Marie Navar, Robert P. Giugliano, Jennifer A. White, Yuliya Lokhnygina, Yale B. Mitchel, Thomas A. Musliner, Christopher P. Cannon, and Michael A. Blazing. “Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin.” J Am Coll Cardiol 75, no. 7 (February 25, 2020): 835–37. https://doi.org/10.1016/j.jacc.2019.12.022.

PMID
32081289
Full Text

Lunsford-Avery, Jessica R., Matthew M. Engelhard, Ann Marie Navar, and Scott H. Kollins. “Author Correction: Validation of the Sleep Regularity Index in Older Adults and Associations with Cardiometabolic Risk.” Sci Rep 10, no. 1 (February 14, 2020): 2993. https://doi.org/10.1038/s41598-020-59762-1.

PMID
32054985
Full Text

Yano, Yuichiro, Jared P. Reis, Cora E. Lewis, Stephen Sidney, Mark J. Pletcher, Kirsten Bibbins-Domingo, Ann Marie Navar, et al. “Association of Blood Pressure Patterns in Young Adulthood With Cardiovascular Disease and Mortality in Middle Age.” Jama Cardiol, January 22, 2020. https://doi.org/10.1001/jamacardio.2019.5682.

PMID
31968050
Full Text

Navar, Ann Marie, Hillary M. Mulder, Daniel M. Wojdyla, and Eric D. Peterson. “Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?” Circ Cardiovasc Qual Outcomes 13, no. 1 (January 2020): e006019. https://doi.org/10.1161/CIRCOUTCOMES.119.006019.

PMID
31918581
Full Text

Pages